D-Cura druppels

D-Cura 2.400 I.E./ml druppels

dcura2400

Bevat geen propylgallaat (E310)
Suikervrij

D-Cura is uitsluitend op recept verkrijgbaar en is opgenomen in het basispakket geneesmiddelen volgens de Zorgwet (wordt volledig vergoed).

Therapeutische indicatie

D-CURA 2.400 I.E. druppels is geïndiceerd voor de behandeling van vitamine D-deficiëntie.

Dosering

Gebruikelijke dosering:*
• Baby’s/kinderen: 6-12 druppels per dag (400 I.E. – 800 I.E. )
• Volwassenen en ouderen: 12-60 druppels per dag (800 I.E. – 4.000 I.E. )

Bij grote hoeveelheden druppels kunnen patiënten de totale dagdosering verdelen over meerdere innames per dag, of er kan overwogen worden om D-Cura drankampullen van 25.000 I.E. voor te schrijven. Voor meer productinformatie verwijzen wij naar de site van het College ter beoordeling van geneesmiddelen (Bijlage 1 samenvatting van de productkenmerken (pdf)).

* De dosering dient individueel te worden vastgesteld door de behandelend arts. Patiënt zijn 25HD serumwaarde, leeftijd, symptomen, huidskleur evenals aanvullende innames van vitamine D dienen in overweging te worden genomen.

Bekijk hier de bijsluiter.

Bekijk hier ons doseringsadvies.

11
AUG
2014

Prevention of microvascular diabetic complications by fenofibrate, Diabetes and Vascular Disease Research

Hermans, Prevention of microvascular diabetic complications by fenofibrate, Diabetes and Vascular Disease Research, 16 May 2011 https://dvr.sagepub.com/cont… https://dvr.sagepub.com/cont…
11
AUG
2014

Effectiveness and tolerability of simvastatine plus fenofibrate for combined hyperlipidaemia (the SAFARI trial)

Grundy, Vega, Yuan, Effectiveness and tolerability of simvastatine plus fenofibrate for combined hyperlipidaemia (the SAFARI trial) Am J Cardiol 2005 https://www.ajconline.org/article/S0002-9149(04)01636-4/abstract
11
AUG
2014

Relative safety of gemfibrozil and fenofibrate in the absence of concomitant cerivastatin use

Holoshitz, Relative safety of gemfibrozil and fenofibrate in the absence of concomitant cerivastatin use, American Journal of Cardiology July 2007 https://www.deepdyve.com/lp/elsevier/relative-safety-of-gemfibrozil-and-fenofibrate-in-the-absence-of-FCiFNLYDfx
11
AUG
2014

Reporting rate of Rhabdomyolysis with fenofibrate+statin versus gemfibrozil+any statin

Jones, Reporting rate of Rhabdomyolysis with fenofibrate+statin versus gemfibrozil+any statin, The American Journal of Cardiology January 2005 https://www.ajconline.org/article/S0002-9149(04)01460-2/abstract
11
AUG
2014

Severe hypertriglyceridemia and pancreatitis: presentation and management Curr Opin Lipidol 2009

Ewald. Hardt, Kloer, Severe hypertriglyceridemia and pancreatitis: presentation and management Curr Opin Lipidol 2009 https://www.ncbi.nlm.nih.gov/pubmed/19770656
11
AUG
2014

ESC/EAS Guidelines for the management of dyslipidaemias

ESC/EAS Guidelines for the management of dyslipidaemias. The task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS) June 2011...
11
AUG
2014

The effects of multiple doses of fenofibrate on the Pharmacokinetics of pravastatin and its 3 alfa hydroxyl isomeric metabolite

Gustavson, Schweitzer, Koehne-Voss, Achari, Chira, Esslinger, Yannicelli, The effects of multiple doses of fenofibrate on the Pharmacokinetics of pravastatin and its 3 alfa hydroxyl isomeric metabolite, J Clinical Pharmacol 2005 https://www.ncbi.nlm.nih.gov/pubmed/16027406
11
AUG
2014

Statin/fibrate combination in patients with metabolic syndrome or diabetes: evaluating the risks of pharmacokinetic drug interactions

Davidson, Statin/fibrate combination in patients with metabolic syndrome or diabetes: evaluating the risks of pharmacokinetic drug interactions, Expert Opin. Drug Saf. 2006 https://www.ajconline.org/article/S0002-9149(10)01041-6/fulltext...
11
AUG
2014

Efficacy and Safety of adding Fenofibrate 160 mg in high-risk patients with mixed hyperlipidemia not controlled by Pravastatin 40 mg monotherapy

Farnier, Ducobu, Bryniarski, Efficacy and Safety of adding Fenofibrate 160 mg in high-risk patients with mixed hyperlipidemia not controlled by Pravastatin 40 mg monotherapy, American Journal of Cardiology, May 2010 https://www.ajconline.org/article/S0002-9149(10)01041-6/fulltext...